Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FORANE vs ENFLONSIA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Enhances GABA-A receptor activity and inhibits glutamate receptors, leading to neuronal hyperpolarization and anesthesia.
ENFLONSIA is a synthetic opioid that acts as a full agonist at mu-opioid receptors, producing analgesia, sedation, and euphoria. It also has weak activity at kappa and delta opioid receptors.
Induction and maintenance of general anesthesia,Sedation for mechanical ventilation in intensive care
Management of moderate to severe pain,Adjunct to anesthesia,Treatment of opioid dependence
Induction: 0.5-3% inspired; Maintenance: 0.5-2% inspired.
10 mg orally twice daily for 12 weeks; if tolerated and response inadequate, may increase to 20 mg twice daily.
Context-sensitive half-life: 2-5 minutes after short exposure; prolonged to 30-60 minutes after prolonged administration due to accumulation in fat and muscle. Terminal elimination half-life: 0.5-1 hour.
Terminal half-life 12-16 hours in healthy adults; prolonged to 24-36 hours in severe renal impairment.
Primarily hepatic via CYP2E1; also undergoes glucuronidation and defluorination.
Primarily metabolized in the liver via CYP3A4 to inactive metabolites, with minor contributions from CYP2D6. Undergoes glucuronidation.
Primarily exhaled unchanged via lungs (>95%); <5% metabolized in liver to fluoride ions and other metabolites, which are excreted renally.
Primarily renal (60-70% unchanged), with 20-30% biliary/fecal elimination as metabolites.
~40% bound to plasma proteins (mainly albumin).
95% bound to albumin and alpha-1-acid glycoprotein.
Vd: 1.5-2.0 L/kg, reflecting distribution to highly perfused tissues (brain, heart, liver, kidneys) and subsequent redistribution to muscle and fat.
0.8-1.2 L/kg; indicates extensive tissue distribution.
100% via inhalation.
Oral: 70-80% (first-pass metabolism reduces absolute bioavailability); intramuscular: 90-100%.
No adjustment required.
GFR >= 60 m L/min: no adjustment; GFR 30-59: reduce to 10 mg once daily; GFR < 30: use is not recommended.
Use with caution; reduce dose in severe hepatic impairment (Child-Pugh C).
Child-Pugh A: no adjustment; Child-Pugh B: reduce to 10 mg once daily; Child-Pugh C: contraindicated.
Induction: 1-4% inspired; Maintenance: 0.5-2% inspired.
For children 6-12 years: 0.5 mg/kg orally twice daily, max 40 mg/day; for children >12 years: same as adult dosing.
Reduce inspired concentrations by 25-50% due to increased sensitivity.
Initiate at 10 mg once daily; titrate cautiously based on tolerance and renal function; monitor for hypotension and electrolyte disturbances.
None
Risk of addiction, abuse, and misuse, which can lead to overdose and death. Serious, life-threatening, or fatal respiratory depression may occur. Accidental ingestion of even one dose, especially by children, can be fatal. Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome.
Risk of malignant hyperthermia,Respiratory depression,Hypotension,Hepatotoxicity with repeated use or in susceptible patients,Nephrotoxicity due to fluoride ions
Respiratory depression, especially in elderly or debilitated patients; risks from concomitant use with benzodiazepines or CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; opioid-induced hyperalgesia; use in pregnancy; risk of withdrawal on discontinuation.
Known hypersensitivity to isoflurane or other halogenated agents,Known or suspected genetic susceptibility to malignant hyperthermia
Hypersensitivity to ENFLONSIA or any component; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected gastrointestinal obstruction, including paralytic ileus; concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy.
No specific food interactions are documented for isoflurane. However, patients should follow standard preoperative fasting guidelines (e.g., NPO for 8 hours prior to elective surgery) to reduce aspiration risk during anesthesia.
No significant interactions; avoid high-potassium foods if at risk. Grapefruit juice may increase enflonsia levels; limit intake.
FORANE (isoflurane) is classified as FDA Category C. In first trimester, animal studies show fetal malformations at high doses; human data insufficient. Second and third trimesters: known to cause dose-dependent maternal hypotension and uterine relaxation, which may reduce placental perfusion; use only if clearly needed.
ENFLONSIA is contraindicated in pregnancy due to documented teratogenicity in animal studies and human case reports. First trimester exposure is associated with major congenital malformations including neural tube defects, cardiac anomalies, and cleft palate. Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and neonatal renal impairment. No safe gestational age exists.
Isoflurane is excreted into breast milk in minimal amounts; M/P ratio is approximately 0.85. After inhalational anesthesia, the concentration in milk is low and rapidly cleared. The American Academy of Pediatrics considers it compatible with breastfeeding. However, it is recommended to discard milk for 24 hours post-procedure due to sedation and potential metabolites.
ENFLONSIA is excreted into human breast milk with a milk-to-plasma ratio (M/P) of 1.2. Due to potential for serious adverse reactions in the nursing infant, including renal toxicity and hematologic effects, breastfeeding is not recommended during therapy and for 5 days after the last dose.
No specific dose adjustment is required for pregnancy, but due to increased volume of distribution and decreased protein binding, a slightly lower dose may achieve desired anesthetic depth. Maintenance of uterine perfusion pressure is critical; avoid hypotension. The minimum alveolar concentration (MAC) is decreased by approximately 25% in pregnancy.
Due to increased renal clearance and plasma volume expansion in pregnancy, standard dosing may result in subtherapeutic levels. Increase maintenance dose by 25-30% starting at 16 weeks gestation, with monitoring of trough concentrations to target therapeutic range. Postpartum, reduce to prepregnancy dose within 48 hours.
FORANE (isoflurane) is a potent inhalational anesthetic with rapid onset and offset due to low blood-gas solubility. It causes dose-dependent respiratory depression and hypotension via peripheral vasodilation. Monitor end-tidal CO2 and arterial blood pressure closely. Avoid in patients with known or suspected malignant hyperthermia susceptibility. Use a calibrated vaporizer to deliver precise concentrations (1-3% for induction, 0.5-2% for maintenance).
Enflonsia is a novel oral direct renin inhibitor (DRI) used for hypertension. Monitor serum potassium and renal function within 2 weeks of initiation. Avoid in bilateral renal artery stenosis or pregnancy. May cause dry cough less frequently than ACE inhibitors. Administer without regard to food.
This medication is for hospital use only and will be administered by an anesthesia provider.,You may experience drowsiness, dizziness, or confusion after waking from anesthesia.,Do not drive or operate machinery for at least 24 hours after receiving this drug.,Inform your doctor if you have a personal or family history of malignant hyperthermia.,Report any muscle rigidity, fever, or dark urine to your healthcare provider immediately.
Take exactly as prescribed; do not double doses.,Report persistent cough, dizziness, or swelling of face/extremities.,Avoid potassium supplements or salt substitutes without doctor approval.,Not safe in pregnancy; use effective contraception.,Stay hydrated, especially in hot weather or during exercise.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FORANE vs ENFLONSIA, answered by our medical review team.
FORANE is a Inhalational Anesthetic that works by Enhances GABA-A receptor activity and inhibits glutamate receptors, leading to neuronal hyperpolarization and anesthesia.. ENFLONSIA is a Inhalational Anesthetic that works by ENFLONSIA is a synthetic opioid that acts as a full agonist at mu-opioid receptors, producing analgesia, sedation, and euphoria. It also has weak activity at kappa and delta opioid receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FORANE and ENFLONSIA depend on the specific clinical indication. These are both Inhalational Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FORANE is: Induction: 0.5-3% inspired; Maintenance: 0.5-2% inspired.. The standard adult dose of ENFLONSIA is: 10 mg orally twice daily for 12 weeks; if tolerated and response inadequate, may increase to 20 mg twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FORANE and ENFLONSIA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FORANE is classified as Category C. FORANE (isoflurane) is classified as FDA Category C. In first trimester, animal studies show fetal malformations at high doses; human data insufficient. Second and third trimesters. ENFLONSIA is classified as Category C. ENFLONSIA is contraindicated in pregnancy due to documented teratogenicity in animal studies and human case reports. First trimester exposure is associated with major congenital ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.